SCHEMBL2679323

SCHEMBL2679323

Cc1ccc(C(=O)Nc2ccc(N3CCOCC3)c(C(F)(F)F)c2)cc1NC(=O)C=Cc1cccnc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 7/20 0.56
MAPT P10636 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
TP53 P04637 1/20 0.53
THRB P10828 1/20 0.53
EGFR P00533 1/20 0.51
HCK P08631 1/20 0.49
NR2C2 P49116 1/20 0.49
BTK Q06187 1/20 0.49
POLB P06746 2/20 0.49
NAMPT P43490 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CSF1R P07333 2/20 0.48
KIT P10721 2/20 0.48
MAPK14 Q16539 1/20 0.47
CYP2C9 P11712 1/20 0.46
PDGFRA P16234 1/20 0.46
KDR P35968 1/20 0.46
RAF1 P04049 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10078170 1.00 BRAF (0.56) BRAFMAPTSMN1; SMN2TP53THRB
SCHEMBL10077601 0.92 BRAF (0.59) BRAFEGFRHCKNR2C2BTK
SCHEMBL2679275 0.92 BRAF (0.59) BRAFEGFRHCKNR2C2BTK
SCHEMBL10078221 0.92 BRAF (0.59) BRAFMAPTSMN1; SMN2TP53THRB
SCHEMBL2679132 0.92 BRAF (0.59) BRAFMAPTSMN1; SMN2TP53THRB
SCHEMBL2678847 0.90 HCK (0.62) BRAFMAPTEGFRHCKNR2C2
SCHEMBL10077759 0.90 HCK (0.62) BRAFMAPTEGFRHCKNR2C2
SCHEMBL2679557 0.88 BRAF (0.66) BRAFEGFRCSF1RKIT
SCHEMBL10077763 0.88 BRAF (0.66) BRAFEGFRCSF1RKIT
SCHEMBL10077755 0.88 CSF1R (0.57) BRAFMAPTEGFRNAMPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US claimed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US claimed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR BRAF 21/4885MAPT 1476/4885SMN1; SMN2 4655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.